- ESUS 2.0 carries a lower recurrence risk (~1%)
- Incomplete diagnostic evaluation after ESUS is associated with increased recurrence
- If you find cancer or athero as a potential mechanism in ESUS, recurrence risk is increased
ahajournals.org/doi/10.1161/…ahajournals.org/doi/10.1161/…
ENRICH-AF trial just presented at ESC: In patients with AF and prior ICH, edoxaban did not reduce the risk of stroke or systemic embolism but increased the risk of major bleeding. The benefit in ischemic stroke reduction was outweighed by ICH risk. clinicaltrialresults.org/wp-…
The #ESCongress#ESO joint session just started!
„Improving outcomes in atrial fibrillation-related stroke: interventions beyond anticoagulation”
We are looking forward to the discussion.
#strokeprevention#Afib#stroke
Blackblue against white. At halftime of the semifinal you get the clear impression that the #fifa and #infantino want Argentina to win. England be brave, you deserve it! #worldcup#engarg
Excellent Clinical Practice article in @NEJM on secondary prevention after ischemic #stroke.
A practical case vignette summarizing contemporary strategies for risk factor management and mechanism-specific prevention.
🔗 tinyurl.com/2hkxntee@JacopoImberti
Early Thrombolysis in Central Retinal Artery Occlusion: Stepping Toward Better Visual Outcomes?
In this #BloggingStroke post, Beatriz Sarno discusses #Stroke article by Xie & Zaslavsky et al. ahajournals.org/do/10.1161/b…